Psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities (PROMPT-ID): a cross-sectional, epidemiological study in Saxony, Germany

Andrea Koch, Julia Dobrindt, Matthias Schützwohl, Andrea Koch, Julia Dobrindt, Matthias Schützwohl

Abstract

Introduction: The psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities study is a cross-sectional, epidemiological study carried out in Saxony, Germany. The main aim of the study is, among others, to assess the prevalence and quality of psychotropic medication in adults with ID.

Methods: Inclusion criteria are mild to profound forms of ID and an age of 18 years or older. A representative sample is realised by a two-stage sampling procedure. Study participants will be recruited from sheltered workshops (SW) and sheltered housings (SH). The stratified cluster sampling is realised by a random selection of service providing institutions followed by a random selection of adults with ID. An estimated total number of n=200 study participants via SW and n=400 via SH will be contacted to obtain data of approximately n=131 study participants recruited through SW and n=232 participants through SH. Thus, based on a psychotropic medication prevalence of 30%, an estimated number of n=109 in-depth interviews about psychotropic prescription practice will be carried out. Data collection is realised through interviews with key carers in the living environment. If psychotropics are prescribed currently, basic information (eg, dosage, treatment duration) are obtained, and a newly developed interview targeting the quality of the psychotropic medication treatment is conducted both with the carers and with the prescribing physicians. In addition to the prevalence and quality of psychotropic treatment, other parameters (eg, mental healthcare utilisation, psychiatric symptomatology, problem behaviour, institutional factors and parameters of the provision area) are assessed using well-established instruments.

Ethics and dissemination: Approval of the responsible ethics committee was obtained. Findings will be disseminated to participating institutions, published in journals and conferences and fill the lack of representative data that is urgently needed in this often criticised health service area. They shall help to improve mental health services in adults with ID prospectively.

Trial registration number: NCT03558815; Pre-results.

Keywords: intellectual disability; psychotherapeutic treatment; psychotropic medication; quality of mental health care provision.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Sampling procedure.
Figure 2
Figure 2
Parameters and interview procedure—carer.

References

    1. Maulik PK, Mascarenhas MN, Mathers CD, et al. . Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2011;32:419–36. 10.1016/j.ridd.2010.12.018
    1. Cooper SA, Smiley E, Morrison J, et al. . Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007;190:27–35. 10.1192/bjp.bp.106.022483
    1. Schützwohl M, Koch A, Koslowski N, et al. . Mental illness, problem behaviour, needs and service use in adults with intellectual disability. Soc Psychiatry Psychiatr Epidemiol 2016;51:767–76. 10.1007/s00127-016-1197-4
    1. Tsiouris JA, Kim SY, Brown WT, et al. . Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord 2013;43:719–31. 10.1007/s10803-012-1617-6
    1. Sheehan R, Hassiotis A, Walters K, et al. . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ 2015;351:h4326 10.1136/bmj.h4326
    1. Bowring DL, Totsika V, Hastings RP, et al. . Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. J Intellect Disabil Res 2017;61:604–17. 10.1111/jir.12359
    1. Doan TN, Lennox NG, Taylor-Gomez M, et al. . Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study. J Intellect Dev Disabil 2013;38:177–81. 10.3109/13668250.2013.778968
    1. Hennicke K. Psychopharmaka in Wohnstätten der Behindertenhilfe Vermutungen über einer zunehmend unerträgliche Situation Hennicke K, Psychopharmaka in der Behindertenhilfe - Fluch oder Segen? Dokumentation der Arbeitstagung der DGSGB am 9.11.2007 in Kassel: Kassel, Germany. Berlin: Eigenverlag der DGSGB, 2008:4–22.
    1. Häβler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm 2015;122:S93–100. 10.1007/s00702-014-1219-x
    1. Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004;25:509–21. 10.1016/j.ridd.2004.03.004
    1. Paton C, Bhatti S, Purandare K, et al. . Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice. BMJ Open 2016;6:e013116 10.1136/bmjopen-2016-013116
    1. Perry BI, Cooray SE, Mendis J, et al. . Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. J Intellect Disabil Res 2018;62(2):140–9. 10.1111/jir.12471
    1. Scheifes A, Egberts TC, Stolker JJ, et al. . Structured Medication Review to Improve Pharmacotherapy in People with Intellectual Disability and Behavioural Problems. J Appl Res Intellect Disabil 2016;29:346–55. 10.1111/jar.12183
    1. Seidel M. Psychopharmaka bei Menschen mit geistiger Behinderung. Ein kritischer Problemaufriss Seidel M, Psychopharmaka bei Menschen mit geistiger Behinderung - Erfüllte und unerfüllte Versprechen - Dokumentation der Arbeitstagung der DGSGB am 12.11.2010 in Kassel. Kassel, Germany. Berlin: Eigenverlag der DGSGB, 2011:4–21.
    1. Deb S, Kwok H, Bertelli M, et al. . Guideline Development Group of the WPA Section on Psychiatry of Intellectual Disability. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 2009;8:181–6. 10.1002/j.2051-5545.2009.tb00248.x
    1. de Leon J, Greenlee B, Barber J, et al. . Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil 2009;30:613–69. 10.1016/j.ridd.2008.10.010
    1. National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. London: NICE, 2015. NICE guideline.
    1. Raghavan R, Patel P. Ethical issues of psychotropic medication for people with intellectual disabilities. Adv Ment Health Intellect Disabil 2010;4:34–8. 10.5042/amhid.2010.0541
    1. Trollor JN, Salomon C, Franklin C. Prescribing psychotropic drugs to adults with an intellectual disability. Aust Prescr 2016;39:126–30. 10.18773/austprescr.2016.048
    1. Bhaumik S, Gangadharan S, Hiremath A, et al. . Psychological treatments in intellectual disability: the challenges of building a good evidence base. Br J Psychiatry 2011;198:428–30. 10.1192/bjp.bp.110.085084
    1. Koslowski N, Klein K, Arnold K, et al. . Effectiveness of interventions for adults with mild to moderate intellectual disabilities and mental health problems: systematic review and meta-analysis. Br J Psychiatry 2016;209:469–74. 10.1192/bjp.bp.114.162313
    1. Thompson Prout H, Browning BK. Psychotherapy with persons with intellectual disabilities: a review of effectiveness research. Adv Ment Health Intellect Disabil 2011;5:53–9. 10.1108/20441281111180673
    1. Vereenooghe L, Langdon PE. Psychological therapies for people with intellectual disabilities: a systematic review and meta-analysis. Res Dev Disabil 2013;34:4085–102. 10.1016/j.ridd.2013.08.030
    1. Beail N. Psychological therapies and people who have intellectual disabilities. Leicester: British Psychological Society, 2016.
    1. Glasenapp J, Schäper S, Barrierefreie Psychotherapie. Möglichkeiten und Grenzen der psychotherapeutischen Versorgung von Menschen mit Intelligenzminderung. Dokumentation der Fachtagung der DGSGB am 11. März 2016 in Kassel. Kassel, Germany. Berlin: Eigenverlag der DGSGB, 2016.
    1. Idusohan-Moizer H, Sawicka A, Dendle J, et al. . Mindfulness-based cognitive therapy for adults with intellectual disabilities: an evaluation of the effectiveness of mindfulness in reducing symptoms of depression and anxiety. J Intellect Disabil Res 2015;59:93–104. 10.1111/jir.12082
    1. Kremeitzl K, Engenhorst A, Simon T, et al. . Zur psychotherapeutischen Versorgung erwachsener Menschen mit Intelligenzminderung in Baden-Württemberg. Psychotherapeutenjournal 2018:135–43. German.
    1. Kufer K, Bengel J. Psychotherapie für Menschen mit geistiger Behinderung – Hintergrunde : Glasenapp J, Schäper S, Barrierefreie Psychotherapie. Möglichkeiten und Grenzen der psychotherapeutischen Versorgung von Menschen mit Intelligenzminderung. Dokumentation der Fachtagung der DGSGB am 11. März 2016 in Kassel. Kassel, Germany. Berlin: Eigenverlag der DGSGB, 2016.
    1. Sappok T, Voß T, Millauer E, et al. . Psychotherapie bei Menschen mit Intelligenzminderung. Theoretischer Hintergrund und praktische Umsetzung. Nervenarzt 2010;81:827–36. German.
    1. Roick C, Kilian R, Matschinger H, et al. . Die deutsche Version des Client Sociodemographic and Service Receipt Inventory - Ein Instrument zur Erfassung psychiatrischer Versorgungskosten. Psychiatr Prax 2001;28(Suppl 2):S84–90.
    1. Fricke U, Günther J, Niepraschk-von Dollen K, et al. . Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen, Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2017 14. aktualisierte amtliche Fassung. Berlin, 2017.
    1. Day JC, Wood G, Dewey M, et al. . A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650–3.
    1. Gasquet I, Villeminot S, Estaquio C, et al. . Construction of a questionnaire measuring outpatients’ opinion of quality of hospital consultation departments. Health Qual Life Outcomes 2004;2:43 10.1186/1477-7525-2-43
    1. Nordon C, Falissard B, Gerard S, et al. . Patient satisfaction with psychotropic drugs: Validation of the PAtient SAtisfaction with Psychotropic (PASAP) scale in patients with bipolar disorder. Eur Psychiatry 2014;29:183–90. 10.1016/j.eurpsy.2013.03.001
    1. Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie? - Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP). Verhaltenstherapie 2014;24:252–63. German 10.1159/000367928
    1. Moss S. PAS-ADD checklist. Brighton: Pavilion Pub, 2002.
    1. Zeilinger EL, Weber G, Haveman MJ. Psychometric properties and norms of the German ABC-Community and PAS-ADD Checklist. Res Dev Disabil 2011;32:2431–40. 10.1016/j.ridd.2011.07.017
    1. Aman MG, Singh NN. Aberrant behaviour checklist—community. East Aurora, NY: Slosson Educational Publications, Inc, 1986.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever